Business Context and Reporting Period
Company: Disc Medicine, Inc. (Nasdaq: IRON)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: Disc Medicine is a clinical-stage biopharmaceutical company focused on developing novel treatments for serious hematologic diseases. The company has no products approved for commercial sale and has not generated any revenue from product sales. Its pipeline includes bitopertin (for erythropoietic porphyrias and Diamond-Blackfan Anemia), DISC-0974 (for anemia of myelofibrosis and chronic kidney disease), and DISC-3405 (for polycythemia vera).
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | 6 Months 2025 | 6 Months 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(55,247) | $(26,352) | $(89,332) | $(53,301) |
| Net Loss Per Share (Basic/Diluted) | $(1.58) | $(1.03) | $(2.61) | $(2.11) |
| Operating Expenses | $61,410 | $30,852 | $101,356 | $62,314 |
| Cash, Cash Equivalents & Marketable Securities | $650,000 | $489,900 | $650,000 | $489,900 |
| Long-Term Debt (Net) | $28,737 | $28,322 | $28,737 | $28,322 |
| Accumulated Deficit | $(387,334) | $(298,002) | $(387,334) | $(298,002) |
Note: Cash and marketable securities balances are as of June 30, 2025. The company reported $127.3 million in cash and cash equivalents and $522.6 million in marketable securities.
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses for the six months ended June 30, 2025, increased by $39.0 million (63%) compared to the same period in 2024. This was driven primarily by a $26.9 million increase in Research and Development (R&D) expenses and a $12.1 million increase in Selling, General, and Administrative (SG&A) expenses.
- R&D Milestone Payments: The increase in R&D expenses included a $10.0 million milestone payment to Roche triggered by the initiation of the APOLLO Phase 3 clinical trial for bitopertin and a $3.0 million milestone payment to AbbVie for DISC-0974.
- Financing Activity: In January 2025, the company completed an underwritten offering of common stock and pre-funded warrants, raising net proceeds of approximately $243.4 million. This significantly bolstered liquidity compared to the prior year.
- Interest Income: Interest income increased to $13.9 million for the six months ended June 30, 2025, from $9.1 million in the prior year period, due to higher cash and marketable securities balances.
Guidance, Outlook, and Risks
- Regulatory Outlook: The company plans to submit a New Drug Application (NDA) in October 2025 for accelerated approval of bitopertin for EPP and XLP, based on the APOLLO trial serving as a post-marketing confirmatory trial.
- Liquidity: Management believes existing cash, cash equivalents, and marketable securities ($650.0 million) are sufficient to fund operations and debt service obligations into 2028.
- Debt Covenants: The company has a $200 million term loan facility with Hercules Capital. As of June 30, 2025, $30 million was drawn. The agreement includes a minimum cash covenant effective January 1, 2027, unless market capitalization exceeds $1.0 billion.
- Material Weakness: The company identified a material weakness in internal controls over financial reporting related to Information Technology General Controls (ITGCs). Remediation efforts are underway, but the weakness remains unremediated as of June 30, 2025.
- Risks: Key risks include the failure of clinical trials, inability to obtain regulatory approval, reliance on third-party manufacturers, and the need for additional capital if development timelines extend or costs increase.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $650 million cash position against the projected burn rate, considering the significant increase in R&D spend.
- Bitopertin NDA Timeline: Monitor the October 2025 NDA submission date and FDA acceptance for filing.
- Internal Controls: Track the progress of remediation for the identified material weakness in ITGCs to ensure future financial reporting reliability.
- Debt Covenants: Review the terms of the Hercules Loan Agreement, specifically the minimum cash covenant triggers starting in 2027.
- Clinical Data: Await data readouts from the APOLLO trial (bitopertin) and ongoing Phase 2 trials for DISC-0974 and DISC-3405.